BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 33530981)

  • 1. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
    Fan Y; Wang J; Jin W; Sun Y; Xu Y; Wang Y; Liang X; Su D
    Mol Cancer; 2021 Feb; 20(1):25. PubMed ID: 33530981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsa_circRNA_102229 facilitates the progression of triple-negative breast cancer via regulating the miR-152-3p/PFTK1 pathway.
    Du C; Zhang J; Zhang L; Zhang Y; Wang Y; Li J
    J Gene Med; 2021 Sep; 23(9):e3365. PubMed ID: 34031947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer.
    Sang Y; Chen B; Song X; Li Y; Liang Y; Han D; Zhang N; Zhang H; Liu Y; Chen T; Li C; Wang L; Zhao W; Yang Q
    Mol Ther; 2019 Sep; 27(9):1638-1652. PubMed ID: 31153828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.
    Ren J; Chen W; Zhou Y; Sun J; Jiang G
    BMC Cancer; 2024 Mar; 24(1):278. PubMed ID: 38429642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    He R; Liu P; Xie X; Zhou Y; Liao Q; Xiong W; Li X; Li G; Zeng Z; Tang H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):145. PubMed ID: 29037220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNA circ-ZEB1 acts as an oncogene in triple negative breast cancer via sponging miR-448.
    Pei X; Zhang Y; Wang X; Xue B; Sun M; Li H
    Int J Biochem Cell Biol; 2020 Sep; 126():105798. PubMed ID: 32629026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
    Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
    Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression.
    Zou Y; Zheng S; Xiao W; Xie X; Yang A; Gao G; Xiong Z; Xue Z; Tang H; Xie X
    Carcinogenesis; 2019 Dec; 40(12):1469-1479. PubMed ID: 31001629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circ-TFCP2L1 Promotes the Proliferation and Migration of Triple Negative Breast Cancer through Sponging miR-7 by Inhibiting PAK1.
    Wang Q; Li Z; Hu Y; Zheng W; Tang W; Zhai C; Gu Z; Tao J; Wang H
    J Mammary Gland Biol Neoplasia; 2019 Dec; 24(4):323-331. PubMed ID: 31776835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The circRNA circIFI30 promotes progression of triple-negative breast cancer and correlates with prognosis.
    Xing L; Yang R; Wang X; Zheng X; Yang X; Zhang L; Jiang R; Ren G; Chen J
    Aging (Albany NY); 2020 Jun; 12(11):10983-11003. PubMed ID: 32497020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
    Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
    Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR.
    Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q
    J Hematol Oncol; 2022 Aug; 15(1):122. PubMed ID: 36038948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis.
    Zhou Y; Ma G; Peng S; Tuo M; Li Y; Qin X; Yu Q; Kuang S; Cheng H; Li J
    Thorac Cancer; 2021 Sep; 12(18):2427-2438. PubMed ID: 34324278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0004676 exacerbates triple-negative breast cancer progression through regulation of the miR-377-3p/E2F6/PNO1 axis.
    Shao G; Fan X; Zhang P; Liu X; Huang L; Ji S
    Cell Biol Toxicol; 2023 Oct; 39(5):2183-2205. PubMed ID: 35870038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.
    Tang H; Huang X; Wang J; Yang L; Kong Y; Gao G; Zhang L; Chen ZS; Xie X
    Mol Cancer; 2019 Feb; 18(1):23. PubMed ID: 30744636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.